JP2019500414A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500414A5
JP2019500414A5 JP2018546742A JP2018546742A JP2019500414A5 JP 2019500414 A5 JP2019500414 A5 JP 2019500414A5 JP 2018546742 A JP2018546742 A JP 2018546742A JP 2018546742 A JP2018546742 A JP 2018546742A JP 2019500414 A5 JP2019500414 A5 JP 2019500414A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
acid substitutions
fgf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500414A (ja
JP7131772B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/073567 external-priority patent/WO2017089016A1/en
Publication of JP2019500414A publication Critical patent/JP2019500414A/ja
Publication of JP2019500414A5 publication Critical patent/JP2019500414A5/ja
Application granted granted Critical
Publication of JP7131772B2 publication Critical patent/JP7131772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2018546742A 2015-11-27 2016-10-03 熱安定性fgf2ポリペプチド及びその使用 Active JP7131772B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802 2015-11-27
EP15196802.1 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (3)

Publication Number Publication Date
JP2019500414A JP2019500414A (ja) 2019-01-10
JP2019500414A5 true JP2019500414A5 (enExample) 2019-12-05
JP7131772B2 JP7131772B2 (ja) 2022-09-06

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546742A Active JP7131772B2 (ja) 2015-11-27 2016-10-03 熱安定性fgf2ポリペプチド及びその使用

Country Status (13)

Country Link
US (1) US11746135B2 (enExample)
EP (1) EP3380508B1 (enExample)
JP (1) JP7131772B2 (enExample)
KR (1) KR102650035B1 (enExample)
CN (1) CN108779158A (enExample)
AU (1) AU2016359722B2 (enExample)
BR (1) BR112018010676A2 (enExample)
CA (1) CA3006388C (enExample)
ES (1) ES2824479T3 (enExample)
LT (1) LT3380508T (enExample)
PL (1) PL3380508T3 (enExample)
SG (1) SG11201804402WA (enExample)
WO (1) WO2017089016A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531B (zh) * 2019-06-19 2022-11-01 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
KR20220142994A (ko) * 2019-09-19 2022-10-24 노쓰웨스턴 유니버시티 인간 유도 다능성 줄기 세포의 비용 효과적인 배양 배지 및 프로토콜
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CN114746436B (zh) * 2019-11-25 2024-07-02 韩国海洋科学技术院 改善温度稳定性和蛋白酶抗性的fgf2多肽及其用途
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
KR20250110924A (ko) * 2022-11-25 2025-07-21 비티엘 헬쓰케어 테크놀로지스 에이.에스. 개선된 안정성을 갖는 fgf-2 폴리펩티드, fgf-2 폴리펩티드를 제조하는 방법 및 그의 용도
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法
KR20240173282A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
KR20240173283A (ko) * 2023-06-02 2024-12-11 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
JPH09503661A (ja) * 1993-09-24 1997-04-15 アメリカン シアナミド カンパニー 繊維芽細胞成長因子の表面ループ構造アナログ
US6083706A (en) 1997-02-26 2000-07-04 Ciblex Corporation Inhibitors of leaderless protein export
US7754686B2 (en) 2000-08-31 2010-07-13 Novartis Vaccines And Diagnostics, Inc. Stabilized FGF formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1444995A1 (en) 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US7816140B2 (en) * 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) * 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
WO2008038287A2 (en) * 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
US9925270B2 (en) 2011-11-28 2018-03-27 The Regents Of The University Of California bFGF-polymer conjugates, methods for making the same and applications thereof
WO2013090919A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
WO2013090911A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins
US9474785B2 (en) * 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181B1 (en) * 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Similar Documents

Publication Publication Date Title
JP2019500414A5 (enExample)
JP2023082054A5 (enExample)
EP4467650A3 (en) Scaffold proteins
AR125394A2 (es) Métodos y composiciones para la expresión génica en plantas
JP2017018125A5 (enExample)
EA201991440A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
JP2018138049A5 (enExample)
JP2018510622A5 (enExample)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2013530689A5 (enExample)
HRP20231496T1 (hr) Cistein proteaza
UA120917C2 (uk) Химерний білок фактора viii та його застосування
RU2013128896A (ru) Сконструированные белки повторов, которые связываются с сывороточным альбумином
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
JP2018506286A5 (enExample)
JP2016519138A5 (enExample)
JP2021505201A5 (enExample)
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
JP2017514522A5 (enExample)
EP1801206A4 (en) PROCESS FOR THE PREPARATION OF L-ARGININE, L-ORNITHIN OR L-CITRULLINE
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.
EP3415158A3 (en) Repeat variable diresidues for targeting nucleotides
MX2024013403A (es) Variantes de gpr156 y usos de estas
JP2018511344A5 (enExample)